1 The mouse corticotroph tumour cell line AtT-20 is a useful model to investigate the physiological role of native somatostatin (SRIF, Somatotropin release inhibitory factor) receptor subtypes (sst 1sst 5 ). The objective of this study was to characterise the pharmacological features and the functional effects of SRIF receptors expressed by AtT-20 cells using radioligand binding and cAMP accumulation. 2 [ 125 I]LTT-SRIF-28, [ 125 I]CGP 23996, [ 125 I]Tyr 10 -cortistatin-14 and [ 125 I]Tyr 3 -octreotide labelled SRIF receptor binding sites with high affinity and in a saturable manner (B max ¼ 315, 274, 239 and 206 fmol mg À1 , respectively). [ 125 I]LTT-SRIF-28 labels significantly more sites than [ 125 I]Tyr 10cortistatin-14 and [ 125 I]Tyr 3 -octreotide as seen previously in cells expressing pure populations of sst 2 or sst 5 receptors. 3 SRIF analogues displaced the binding of the four radioligands. sst 2/5 receptor-selective ligands showed much higher affinity than sst 1/3/4 receptor-selective ligands. The binding profile of [ 125 I]Tyr 3octreotide was different from that of [ 125 I]LTT-SRIF-28, [ 125 I]CGP 23996 and [ 125 I]Tyr 10 -cortistatin-14. The sst 5/1 receptor-selective ligand L-817,818 identified two binding sites, one with subnanomolar affinity (sst 5 receptors) and one with micromolar affinity (sst 2 receptors); however, the proportions were different: 70 -80% high affinity with [ 125 I]LTT-SRIF-28, [ 125 I]CGP 23996, [ 125 I]Tyr 10 -cortistatin-14, but only 20% with [ 125 I]Tyr 3 -octreotide.
Introduction
Somatostatin (SRIF; somatotropin release inhibitory factor) is known to be a potent regulator of endocrine secretion (Hannon et al., 2002a) . In particular, in the anterior pituitary, SRIF acts as a neurohormone, secreted from neurones into the blood, and inhibiting the secretion of growth hormone (GH), adrenocorticotropin (ACTH) as well as other pituitary hormones. Biological actions of SRIF are exerted through the activation of multiple heptahelical, G-protein-linked SRIF receptor subtypes (sst 1 -sst 5 ) which are generally coupled to an inhibition of cAMP levels (Patel, 1999) . SRIF receptors have a broad and overlapping tissue distribution; in particular, in the rat pituitary, sst 2 and sst 5 receptors are the principal subtype expressed (Mezey et al., 1998) . To date, although numerous studies have explored the SRIF receptor function when expressed in transfected systems, assigning a pharmacological and functional profile to an individual native SRIF receptor remains difficult. This is due to the limited availability of
